NBTX NBTX
Company Profile ↓Company Overview
NBTX (NBTX) is a publicly traded company listed on with a market capitalization of $1.92B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 28.4%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $29.64M (-355.3% YoY); net profit $-23.96M.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +474.93% |
| 6 Months: | +85.03% |
| 3 Months: | +14.09% |
| 1 Month: | +2.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)52.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 28.4%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 28.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 30.06M | -11.61M | 29.64M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 46.70M | 56.84M | 56.78M | 40.46M |
| Operating Income | - | -46.70M | -26.78M | -68.39M | -10.82M |
| EBITDA | - | -49.70M | -30.09M | -58.33M | -12.07M |
| Interest Expense | - | 5.84M | 7.98M | 8.09M | 10.39M |
| Pretax Income | - | -57.03M | -39.58M | -68.03M | -23.96M |
| Tax Provision | - | 10.00K | 120.00K | 101.00K | 3.00K |
| Net Income | - | -57.04M | -39.70M | -68.13M | -23.96M |
| Diluted EPS | - | -1.64 | -1.08 | -1.44 | -0.50 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 59.77M | 93.90M | 67.42M | 67.76M |
| Current Assets | - | 52.36M | 87.34M | 61.47M | 62.75M |
| Cash & Equivalents | - | 41.39M | 75.28M | 49.74M | 52.75M |
| Inventory | - | - | - | - | - |
| Receivables | - | 101.00K | 905.00K | 2.98M | 2.14M |
| Total Liabilities | - | 86.81M | 95.74M | 133.12M | 152.24M |
| Current Liabilities | - | 37.94M | 49.87M | 58.94M | 57.51M |
| Long Term Debt | - | 44.04M | 41.66M | 43.01M | 89.12M |
| Total Debt | - | 53.17M | 50.56M | 50.90M | 95.32M |
| Total Equity | - | -27.05M | -1.84M | -65.70M | -84.48M |
| Shares Outstanding | - | 34.88M | 47.13M | 47.43M | 48.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -37.10M | -12.48M | -19.55M | -33.42M |
| Investing Cash Flow | - | 138.00K | -349.00K | -955.00K | -578.00K |
| Financing Cash Flow | - | -5.65M | 46.77M | -5.13M | 37.42M |
| Capital Expenditure | - | -93.00K | -337.00K | -848.00K | -546.00K |
| Free Cash Flow | - | -37.20M | -12.81M | -20.40M | -33.97M |
| Net Change in Cash | - | -42.62M | 33.95M | -25.64M | 3.42M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | -89.1% | 589.1% | -36.5% |
| Net Margin % | - | - | -132.1% | 586.8% | -80.8% |
| ROE % | - | 210.9% | 2,152.9% | 103.7% | 28.4% |
| ROCE % | - | -213.9% | -60.8% | -806.2% | -105.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NBTX
Nanobiotix Reports 54.5M Theoretical Voting Rights for June 30 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNeGp1b3ZDZEtzSzl0T2RkejdrZ2RhaWp4TjMybXl6ajZfSXhqTVJEOHYzcHpsU200OXdybERtQ3JtX2NDMHo2M3FHWU4yR2xVLWN6TUVqQnNOM1RvZkRhQmlLMlFvOFNpOUtfYlRiQ2FjMzZ2QlFiQXVveWVsX3Z6Tk1Yb2xoTFl2TGlGRF…
Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform (NASDAQ:NBTX) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxOSjktQmFmaUpRV1otTVF1dWFxblFrbGU5a2JIZU94dkdVZm1NWHJWVEVLd1FOX2R6b2RpeFpveDN5YkYwVkJIZEg4MVY1WUVXN19nc3BCXzJoTkJjdGhsWTFMMUZQejFDdjhxeFR2VEg1RGhoekxTbW9hWEotRTFzMWVJbTdfVzJuUDhRNW…
Nanobiotix (NBTX) Provides Update on Operational Progress - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQYUlWMWVTdDdabXM4WGJJdHhsQkNGc0IydFF2TVFlZWFRNWdsM2JjUDF1NHQ1dDV4WUNIYThmTGM2dXg2RzVtZnljNXFUZVFjZlNjV2lCNVV1SmRoZlNONXpKNzkxTXFESW5YbmcycU9lNm9UUzY5ZmNrMHA4X1dyTFdIVVUxWmtfSVJSNS…
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOeUlLQlNDU2o0MUpKYkJvLVhldnNXV3ppbG9hbGNFZk9ITHduMWJkZFdZam95Vld6X09nbVJiQUFzLUVnSG9jdTVfajQ1V1RmX3ZQbHd6elZmeW1jM1lCNFV3SnBhY1l3cDBYeG9vRDdWNGRqWWJzSEhRUlJ6dXNva2dkWndlU0YzbFB1bj…
Top Cybin (HELP) Competitors 2026 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxPYmxXdmY0Z2V0WW9ORnYzSGlBSndTUU44NXlrNVdZQzJLamdpc2Q1LTVXX2JNVDkwdDVBR2pNUjgxZlg0ajFRaHpLa3drTzU1V1RCNXBIMEliRlZaaFJNc3VwREhLYWl0S2pFb05LQm50M0JXZ0p0OFdzUWhtSDJLOA?oc=5" target="_…
Nanobiotix (Nasdaq: NBTX) reports June 2026 voting rights totals - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPTVEtV0R0SHpycHhjRTlQTXI1NkhoVDI2M0VabDVON0ZMTVlxY1V4VkRVWHU0TGFCVzN1elljMk9yaDYwSmtjZXJkay1fRVZnZ1Mtcm04NlhlNVkzM1dYWDRlejZibFYzTFF4SlVkbFpnbWh1NE9pczJVTTZ1M2VrMmRhTVIxTDdsWTRIT1…
NBTX — Frequently Asked Questions
What is the current share price of NBTX?
As of 2026-08-05 17:25 PDT, NBTX trades at $39.67 on NASDAQ/NYSE. Its 52-week range is $6.90 to $55.07.
What is the market capitalisation of NBTX?
NBTX has a market capitalisation of $1.92B on NASDAQ/NYSE.
What is the P/E ratio of NBTX?
NBTX trades at a trailing price-to-earnings (P/E) ratio of -79.34. Its price-to-book (P/B) ratio is -22.73.
What is the return on equity (ROE) of NBTX?
NBTX has a return on equity (ROE) of 28.36%. Its return on capital employed (ROCE) is -105.51%.
Is NBTX a good stock to buy?
This page provides a data-driven analysis of NBTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.